{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Hyperphosphataemia (serum phosphorus \\>1.78 mmol/L) among participants during the preceding 6 months of conventional vitamin D therapy was derived from retrospective data collection in case report form, reported at baseline. Conventional vitamin D therapy included vitamin D supplement products from ATC group A11CC (vitamin D and analogues).","groups":[{"description":"Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)","id":"OG000","title":"End-stage Kidney Disease With Secondary Hyperparathyroidism"}],"paramType":"NUMBER","populationDescription":"Participants with available retrospective data","reportingStatus":"POSTED","timeFrame":"6 months prior to start of study through baseline","title":"Number of Participants With Hyperphosphataemia During Preceding Conventional Vitamin D Therapy","type":"SECONDARY","unitOfMeasure":"participants"}